E 2212Alternative Names: E-2212
Latest Information Update: 25 Mar 2017
At a glance
- Originator Eisai Inc
- Class Antidementias
- Mechanism of Action Amyloid precursor protein secretase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in USA (PO)